Andreas is specialized in antibody discovery, toxinology, and snakebite antivenom. He holds a PhD from the University of Copenhagen, and a M.Sc. Eng. from the Technical University of Denmark. He is co-founder of the companies Biosyntia, VenomAb, Antag Therapeutics, Chromologics, and Bactolife. Furthermore, Andreas is recognized as Denmark’s Coolest Engineer, Top 10 Biotech Entrepreneur under 30 in Europe 2016, Top 6 Entrepreneurial Academic under 35 in Europe 2017, 30 under 30 by Forbes 2017, and a Top 35 Innovator under 35 by MIT Technology Review 2017. Recently, he has been appointed as an advisor at the WHO Snakebite Envenoming Group.
Dr. Aneesh Karatt-Vellatt is a Group leader at Iontas Ltd, an antibody drug discovery company based in Cambridge, UK. Aneesh joined Iontas after completing a PhD in Biochemistry from the University of Cambridge. At Iontas, a team lead by Dr. Karatt-Vellatt developed a novel platform technology that facilitates antibody generation against traditionally difficult therapeutic targets such as ion channels and GPCR’s. He is also a key member of an international scientific consortium that aims to develop recombinant antivenoms based on human IgG monoclonal antibodies to treat snakebites.
... more coming soon!